FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 788 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Brothers Break Down After Seeing Their Parents For First Time In... October 31, 2021 Begin Each Day… January 20, 2021 Time to get stratified January 10, 2023 How serendipity sent this oncologist in search of a cure for... August 12, 2022 Load more HOT NEWS A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target... Hospice Service Provides “Bucket List” Tattoo for 77-Year-Old Woman with Breast... FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL Liquid Biopsy May Predict Risk of Breast Cancer Returning Years Later
